CRYOPORT INC (CYRX)
US2290503075 - Common Stock
Overall CYRX gets a fundamental rating of 2 out of 10. We evaluated CYRX against 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of CYRX have multiple concerns. CYRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CYRX has reported negative net income.
In the past year CYRX has reported a negative cash flow from operations.
In the past 5 years CYRX always reported negative net income.
CYRX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CYRX (-11.23%) is comparable to the rest of the industry.
CYRX has a Return On Equity (-22.00%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.23% | ||
| ROE | -22% | ||
| ROIC | N/A |
ROA(3y)-13.69%
ROA(5y)-13.63%
ROE(3y)-24.78%
ROE(5y)-21.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CYRX has a Gross Margin of 42.58%. This is comparable to the rest of the industry: CYRX outperforms 46.55% of its industry peers.
In the last couple of years the Gross Margin of CYRX has declined.
CYRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5Y-3.93%
2. Health
2.1 Basic Checks
CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYRX has been increased compared to 5 years ago.
Compared to 1 year ago, CYRX has a worse debt to assets ratio.
2.2 Solvency
CYRX has an Altman-Z score of 0.71. This is a bad value and indicates that CYRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.71, CYRX is doing worse than 67.24% of the companies in the same industry.
A Debt/Equity ratio of 0.78 indicates that CYRX is somewhat dependend on debt financing.
CYRX has a worse Debt to Equity ratio (0.78) than 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.71 |
ROIC/WACCN/A
WACC10.48%
2.3 Liquidity
A Current Ratio of 11.73 indicates that CYRX has no problem at all paying its short term obligations.
CYRX has a better Current ratio (11.73) than 93.10% of its industry peers.
A Quick Ratio of 11.16 indicates that CYRX has no problem at all paying its short term obligations.
The Quick ratio of CYRX (11.16) is better than 93.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.73 | ||
| Quick Ratio | 11.16 |
3. Growth
3.1 Past
CYRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.56%.
Looking at the last year, CYRX shows a decrease in Revenue. The Revenue has decreased by -1.69% in the last year.
The Revenue has been growing by 64.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-136.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-445.83%
Revenue 1Y (TTM)-1.69%
Revenue growth 3Y43.64%
Revenue growth 5Y64.1%
Revenue growth Q2Q-5.14%
3.2 Future
CYRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.88% yearly.
The Revenue is expected to grow by 9.84% on average over the next years. This is quite good.
EPS Next Y39.68%
EPS Next 2Y24.86%
EPS Next 3Y18.88%
EPS Next 5YN/A
Revenue Next Year4.74%
Revenue Next 2Y7.72%
Revenue Next 3Y9.84%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CYRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYRX's earnings are expected to grow with 18.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.86%
EPS Next 3Y18.88%
5. Dividend
5.1 Amount
No dividends for CYRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CRYOPORT INC
NASDAQ:CYRX (5/1/2024, 10:05:50 AM)
16.57
+0.38 (+2.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap814.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.23% | ||
| ROE | -22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.58% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.73 | ||
| Quick Ratio | 11.16 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-136.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y39.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.69%
Revenue growth 3Y43.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y